Complex problems, bold solutions
We pioneer therapies for prevalent disorders by combining precision delivery with a controllable therapeutic.
Our strategy is set apart by an innovative "human-first" approach, where the initial stages of therapeutic development occur entirely in human neural circuitry recreated in our lab. As a result, our proprietary technologies allow predictable translation from bench to bedside, an enhanced safety profiles of our therapies in the clinic, and ultra-low development costs that is scalable to meet the unmet needs of millions of patients across the world.
In the clinic, delivery of our therapies will be minimally invasive using a low vector dose. When combined with our technology, this approach unlocks a broad range of prevalent disorders as therapeutic targets with disease modifying patient outcomes to establish a new standard of healthcare.
PRECISION DELIVERY
We have proprietary technologies that harness our "human-first" approach to engineering cell-type specific gene delivery vectors.
Our platforms effectively recreate functional human neural circuits in the lab, allowing efficient and high throughput identification of new therapeutic vectors with the goal of maximising translatability into patients.
CIRCUIT CONTROL
Neurons communicate through electrical activity. By normalising dysfunctional electrical activity in neural circuits, we can treat a broad range of prevalent disorders.
Our system for this neuromodulation works as an adjustable 'remote control' for selectively altering aberrant neuronal activity.
In the clinic, patients first receive an injection of our therapy that is expressed only in targeted neurons. Our therapy is safe and remains dormant until the patient consumes an oral medicine which activates it. In this way, patients and clinicians can treat dysfunctional neural circuits and ultimately treat the root cause of their disorder.
OUR PIPELINE
Our targeted and controllable therapies are capable of treating millions of patients that do not currently have effective treatment options.
We are on track for clinical trials in 2026 for our first indication in spasticity, one of the most common motor disorders that can cause highly debilitating symptoms for patients. Our pipeline also includes to further undisclosed indications in areas of high unmet need.
